Dynamin 1-mediated endocytic recycling of glycosylated N-cadherin sustains the plastic mesenchymal state to promote ovarian cancer metastasis
Epithelial-to-mesenchymal transition (EMT) is a key process that confers metastatic plasticity to ovarian cancer cells, enabling them to disseminate aggressively throughout the peritoneal cavity and contributing to poor clinical outcomes for patients. However, a pharmacologically exploitable driver of EMT in ovarian cancer has yet to be identified. To address this, we utilized a master regulators algorithm to prioritize EMT regulators from a dataset of over 8,000 patient samples, including multidimensional omics data from more than 20 cancer types in TCGA. Further analysis identified dynamin-1 (DNM1), an endocytic regulator, as a novel master regulator of EMT in ovarian cancer. Clinically, DNM1 overexpression was found to be associated with the mesenchymal subtype and advanced/metastatic stages of ovarian carcinomas. Molecular assays revealed that DNM1 upregulates N-cadherin, a hallmark mesenchymal marker, by promoting its endocytosis and recycling, thereby inducing cell polarization and motility. In addition, integration of ATAC-seq and RNA-seq analyses uncovered the repression of beta-1,3-galactosyltransferase (B3GALT1), a glycosyltransferase, in metastatic cells. B3GALT1-mediated glycosylation hindered the recycling of N-cadherin. Functional studies demonstrated that depletion of DNM1 or pharmacological inhibition of endocytic recycling significantly impaired cell polarity, migration, and also cancer stemness. Importantly, in vivo experiments showed that the loss of DNM1 significantly suppressed peritoneal metastatic colonization. Interestingly, metastatic cells with elevated DNM1-mediated endocytosis showed increased susceptibility to nanoparticle delivery. Collectively, these results establish the DNM1-N-cadherin axis as an important regulator of EMT-associated ovarian cancer metastasis and suggest its potential as a biomarker for targeted nanodrug therapy.